Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.

ABSTRACT:

Purpose

New therapies have changed the outlook for patients with multiple myeloma, but novel agents are needed for patients who are refractory or relapsed on currently approved drug classes. Novel targets other than CD38 and BCMA are needed for new immunotherapy development, as resistance to daratumumab and emerging anti-BCMA approaches appears inevitable. One potential target of interest in myeloma is ICAM1. Naked anti-ICAM1 antibodies were active in preclinical models of myeloma and safe in patients, but showed limited clinical efficacy. Here, we sought to achieve improved targeting of multiple myeloma with an anti-ICAM1 antibody-drug conjugate (ADC).

Experimental design

Our anti-ICAM1 human mAb was conjugated to an auristatin derivative, and tested against multiple myelom

SUBMITTER: Sherbenou DW 

PROVIDER: S-EPMC7669584 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature